This post was originally published on this site Maintenance therapy with Rubraca (rucaparib) tablets continues to benefit women with recurrent ovarian cancer after weighing in patients’ perceptions about their health, disease symptoms, and treatment toxicity, a retrospective analysis of Clovis Oncology‘s ARIEL3 Phase 3 clinical trial found. The data were presented recently at the International Society…
This post was originally published on this site Oncopeptides is preparing to submit a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) to seek accelerated approval of Ygalo (melflufen) to treat patients with triple-refractory multiple myeloma. Ygalo is a lipophilic peptide-conjugated alkylator that works by rapidly delivering a cancer-killing agent (an alkylating…
This post was originally published on this site A Phase 1/2 clinical trial has started dosing participants to test EnGeneIC‘s second-generation cytotoxic-loaded EDV nanocells as a treatment for EGFR-positive solid cancers who have exhausted all other therapeutic alternatives. The Carolyn Trial (ACTRN12619000385145), still recruiting participants at the Frankston Private Hospital in Victoria, Australia, is expected to…
This post was originally published on this site Keytruda (pembrolizumab), Merck‘s anti-PD-1 checkpoint blockade immunotherapy, failed to prolong the overall survival of patients with metastatic triple-negative breast cancer (TNBC) beyond that provided by chemotherapy agents, a Phase 3 trial shows. Checkpoint blockade immunotherapies are based on the principle of removing the “brakes” of our immune…
This post was originally published on this site The most recent statistics surrounding family caregiving in the United States are staggering. A 2005 National Alliance for Caregiving report estimates that 65.7 million Americans are familial caregivers. Of that number, more than 16 million care for people with dementia or Alzheimer’s disease. Shockingly, some of those…
This post was originally published on this site The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded $1.5 million to Oryzon Genomics to support expanding an ongoing Phase 2a trial assessing the potential of vafidemstat (ORY-2001) in patients with mild to moderate Alzheimer’s disease to the United States. The double-blind, placebo-controlled trial (2017-004893-32), called ETHERAL, is…
This post was originally published on this site The Prostate Cancer Foundation (PCF) has released its comprehensive Prostate Cancer Patient Guide with the latest in diagnosis, research, treatments, and lifestyle factors for patients and caregivers. With contributions from leading physicians and scientists, the free guide is aimed at patients who have recently been diagnosed, are…
This post was originally published on this site IBI301, a biosimilar of Rituxan (rituximab), behaves similarly in the body and has a similar efficacy as the original product in patients with B-cell cancers, according to results from two clinical trials in China, IBI301’s co-developers, Innovent Biologics and Eli Lilly, has announced. “The results of clinical…
This post was originally published on this site Xtandi (enzalutamide), an androgen receptor inhibitor, significantly delays disease progression — as assessed through radiological imaging — or death in metastatic hormone-sensitive prostate cancer (mHSPC) patients, a Phase 3 clinical trial shows. The benefits were seen independently of patients’ initial PSA levels, suggesting that, contrary to prior beliefs, PSA…
This post was originally published on this site Combining Immunogen‘s mirvetuximab soravtansine, an investigational antibody-drug conjugate, with Avastin (bevacizumab) showed signs of favorable efficacy and demonstrated a manageable safety profile in patients with platinum-resistant ovarian cancer, according to data from a Phase 1/2 clinical trial. In addition, initial data from a Phase 1 trial also…
